Pet Cancer Therapeutics Market Scope
Over the past few decades, global pet cancer prevalence has been increased drastically, which will ultimately upsurge the demand for Pet Cancer Therapeutics. In addition to this, increasing spending on Animal care and growing awareness and routine checkups for the animals will ultimately upsurge the demand for the same. Moreover, the inclusion of technologically advanced therapies such as Chemotherapy, Targeted Therapy, Combination Therapy, Immunotherapy, and many others will create vigorous opportunities for pet cancer treatments.
The market study is being classified by Type (Chemotherapy Drugs and Vaccines), by Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary, Squamous Cell Cancer and Others) and major geographies with country level break-up. According to AMA, the Global Pet Cancer Therapeutics market is expected to see growth rate of 12.76% and may see market size of USD319.18 Million by 2024.
The Players having a strong hold in the market are Aratana Therapeutics, AB Science, Boehringer Ingelheim International, Nippon Zenyaku Kogyo, and Morphogenesis. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Pet Cancer Therapeutics market throughout the predicted period.
Aratana Therapeutics Inc (United States), AB Science (France), Boehringer Ingelheim International GmbH (Germany), Nippon Zenyaku Kogyo Co.Ltd. (Japan), Morphogenesis Inc. (United States), VetDC, Inc. (United States), Karyopharm Therapeutics Inc. (United States), Rhizen Pharmaceuticals SA (Switzerland), Regeneus Ltd (Australia) and Oasmia Pharmaceutical AB (Sweden) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Zoetis Inc (United States), Torigen Pharmaceuticals, Inc. (United States) and CanFel Therapeutics (United States).
AdvanceMarketAnalytics has segmented the market of Global Pet Cancer Therapeutics market by Type, Application and Region.
On the basis of geography, the market of Pet Cancer Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North Amercia region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.
Market Leaders and their expansionary development strategies
In April 2019, Elanco Animal Health has signed an agreement to acquire Aratana Therapeutics, pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats.
In April 2019 Elanco has signed a development and commercialization agreement with VetDC for Tanovea-CA1, the first U.S. Food and Drug Administration (FDA) conditionally approved canine lymphoma treatment. Moreover, in Jan 2018, Aratana Therapeutics has been granted conditional approval for its canine osteosarcoma vaccine, Live Listeria Vector(AT-014), by the USDA's Center for Veterinary Biologics.
The government of the United States has mandated to register the pet care pharmaceutical products as well as other pesticide products with the US Environmental Protection Agency (EPA) and with each state where the product is sold.
- Increasing Technological Enhancements In Treatments for Mast Cell Cancer and Melanoma
- Introduction to Internet / Mobile Pet Care will Simplify Pet Care Treatments
- Upsurging Investments in Animal Care
- Increasing Prevalence of Pet Cancer across the Globe
- Improved Pet Care Infrastructure across Emerging Economies
- Favorable Government Reimbursement in Pet Cancer Therapeutics
- Lack of Awareness from the Underdeveloped Regions
- Escalating Prices for Cancer Treatment Products across the Globe
- Stringent Government Regulations related to Cancer Therapeutics Development
Key Target Audience
Pet Cancer Treatment Providers, Pet Cancer Medicine Manufacturers, Pet Cancer Medicine Distributors and Suppliers, Animal Healthcare Industry Associations, Petcare Industry Associations, Research and Development Institutes, Government Agencies and Others
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase